CLOVER HEALTH ($CLOV) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of -$0.05 per share, beating estimates of -$0.11 by $0.06. The company also reported revenue of $487,710,000, beating estimates of $476,397,120 by $11,312,880.
Stock price change since market close: -1.38%
You can see Quiver Quantitative's $CLOV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CLOVER HEALTH Insider Trading Activity
CLOVER HEALTH insiders have traded $CLOV stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 7 sales selling 65,437 shares for an estimated $203,718.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CLOVER HEALTH Hedge Fund Activity
We have seen 82 institutional investors add shares of CLOVER HEALTH stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP removed 3,523,047 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,780,523
- RENAISSANCE TECHNOLOGIES LLC removed 3,221,559 shares (-41.8%) from their portfolio in Q4 2025, for an estimated $7,570,663
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 2,768,088 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,505,006
- BLACKROCK, INC. added 1,885,917 shares (+6.2%) to their portfolio in Q4 2025, for an estimated $4,431,904
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,878,719 shares (-70.7%) from their portfolio in Q4 2025, for an estimated $4,414,989
- DIMENSIONAL FUND ADVISORS LP added 1,494,043 shares (+69.8%) to their portfolio in Q4 2025, for an estimated $3,511,001
- JANE STREET GROUP, LLC removed 1,380,091 shares (-70.2%) from their portfolio in Q4 2025, for an estimated $3,243,213
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CLOVER HEALTH Analyst Ratings
Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for CLOVER HEALTH, check out Quiver Quantitative's $CLOV forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
